Clin2
NCT07288320Possibly a fitRecruiting

Testing NBI-1117568 for bipolar I mania

Bipolar I DisorderMania

Treatments studied

Part of Brain & nervous system clinical trials.

This trial tests an experimental drug called NBI-1117568 for people with bipolar I disorder who are currently having a manic or mixed episode. The goal is to see if the drug helps calm mania symptoms and is safe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have been diagnosed with bipolar I disorder
  • You have had at least one manic episode in the past that needed treatment
  • You are currently having a manic or mixed episode (with or without psychotic symptoms)
  • You do not have any unstable or poorly controlled medical condition (like heart, liver, kidney, or other chronic disease)
  • You have not been hospitalized for a psychiatric reason for 30 or more days in a row in the last 3 months
  • You have not taken clozapine for treatment-resistant psychosis

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07494305Recruiting· Phase 2
Testing a new drug for bipolar depression

This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.

Bentonville, Arkansas
NCT05977023Recruiting· Phase 2
NMDA-targeted medicine to treat bipolar I depression

This Phase 2 study tests a medication that works on NMDA receptors to improve depression symptoms in people with bipolar I disorder. It may help if you’re currently in a bipolar depression episode and other mood treatments haven’t fully controlled it.

Taichung
NCT06786624Recruiting· Phase 3
Testing a new drug for depression that hasn't fully responded to treatment

This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.

Little Rock, Arkansas
NCT06963034Recruiting· Phase 3
Study of a new medicine for adults with schizophrenia

This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.

Bryant, Arkansas
NCT07114874Recruiting· Phase 3
A long-term study of a new drug for schizophrenia

This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.

Bryant, Arkansas
NCT07365462Recruiting· Phase 2
Study of NBI-1065890 for tardive dyskinesia in adults

This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.

Bryant, Arkansas

Hear when a new Bipolar I Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.